心肌梗死后早期68Ga-FAPI-46 PET/CT可识别LVEF保留的STEMI患者不良重构与心血管事件高风险
该前瞻性研究纳入50例成功接受直接PCI的STEMI患者,在术后六天内行68Ga-FAPI-46 PET/CT量化成纤维细胞活化体积(FAV)。FAV与一年时左室舒张末内径(LVEDD)正相关并独立预测LVEDD>50 mm,高FAV组三年主要不良心血管事件(MACE)发生率显著高于低FAV组(47.22% vs. 14.29%,p=0.031),将FAV二分类纳入传统临床模型可改善两年MACE的判别与重分类。
要点
- STEMI成功PCI后六天内行68Ga-FAPI-46 PET/CT所测FAV与一年LVEDD正相关,并独立预测LVEDD>50 mm。
- 以FAV 51.6为界,高FAV组三年MACE发生率显著高于低FAV组(47.22% vs. 14.29%,p=0.031)。
- FAV加入传统临床模型改善两年MACE判别(AUC 0.84 vs. 0.70,p=0.021)及重分类。
核心结论
- 在LVEF保留的STEMI患者中,早期68Ga-FAPI-46 PET/CT所测FAV与后续左室重构相关,并可能提供超越传统危险因素的增量预后价值。
- 作者指出上述发现为探索性,需在更大规模多中心队列中验证并与其他相关影像方法比较。
研究设计与样本
- 前瞻性研究,最终纳入50例成功接受直接PCI的STEMI患者。
- 患者在成功PCI后六天内接受68Ga-FAPI-46 PET/CT以量化成纤维细胞活化体积(FAV)。
- 主要终点为三年内主要不良心血管事件(MACE),包括卒中、再发心肌梗死、心衰再入院、靶血管或非靶血管血运重建及新发心房颤动;一年时LVEDD为次要结局。
主要发现
- 基线FAV与一年LVEDD呈正线性相关(r=0.298,p=0.036),并独立预测LVEDD>50 mm(OR 1.022,95%CI 1.007-1.038,p=0.004)。
- 校正分析中,FAV每增加一个单位与MACE风险升高1.1%相关;FAV≤81.34时每单位升高对应MACE风险增加5%(HR 1.05,95%CI 1.003-1.098,p=0.035)。
- 以最佳FAV界值51.6分组,高FAV组MACE显著多于低FAV组(47.22% vs. 14.29%,p=0.031)。
- 将二分类FAV纳入传统临床模型改善两年MACE判别(AUC 0.84 vs. 0.70,p=0.021),并提供显著净重分类改善(NRI 0.506,p<0.001)和综合判别改善(IDI 0.212,p<0.001)。
关键数值与推荐
- 高FAV组与低FAV组以FAV 51.6为界划分,两组三年MACE发生率分别为47.22%与14.29%(p=0.031)。
- FAV≤81.34时,每单位升高对应MACE风险HR 1.05(95%CI 1.003-1.098,p=0.035)。
- 二分类FAV加入传统临床模型后两年MACE的AUC为0.84,传统模型为0.70(p=0.021)。
临床怎么用
- 对成功PCI的STEMI患者在早期行68Ga-FAPI-46 PET/CT量化FAV,可能有助于识别LVEF保留但左室重构及MACE风险较高的患者。
- FAV可作为传统临床模型之外的增量预后指标,但当前证据为探索性,尚不能据此改变常规临床决策。
局限性
- 样本量仅50例,作者明确称结果为探索性,需更大规模多中心队列验证。
- 需与其他相关影像方法进行比较以确认FAV的增量价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fibroblast activation protein (FAP)-targeted PET/CT with radiolabeled FAPIs enables noninvasive visualization of fibroblast activity following ST-segment elevation myocardial infarction (STEMI). However, the prognostic implications of myocardial FAPI uptake remain insufficiently characterized. OBJECTIVES: This prospective study aimed to evaluate the prognostic value of 68Ga-FAPI-46 PET/CT in STEMI patients treated successfully with primary percutaneous coronary intervention (PPCI). METHODS: Within six days after successful PPCI, patients underwent 68Ga-FAPI-46 PET/CT to quantify fibroblast activation volume (FAV). The primary endpoint was the occurrence of major adverse cardiovascular events (MACEs) over three years, including stroke, recurrent myocardial infarction, heart failure readmission, target or non-target vessel revascularization, and new-onset atrial fibrillation. Left ventricular end-diastolic diameter (LVEDD) at one year was assessed as a secondary outcome. RESULTS: A total of 50 STEMI patients were finally included in this study. Baseline FAV showed a positive linear correlation with one-year LVEDD (r = 0.298, p = 0.036) and independently predicted LVEDD > 50 mm (OR 1.022, 95% CI 1.007-1.038, p = 0.004). In adjusted analysis, each unit increase in FAV was associated with a 1.1% higher risk of MACEs. A nonlinear relationship was observed, with FAV ≤ 81.34 corresponding to a 5% increase in MACE risk per unit rise (HR 1.05, 95% CI 1.003-1.098, p = 0.035). Using an optimal FAV cutoff of 51.6, patients with high FAV had significantly more MACEs than those with low FAV (47.22% vs. 14.29%, p = 0.031). Incorporating dichotomized FAV into a conventional clinical model was associated with improved discrimination of two-year MACEs (AUC 0.84 vs. 0.70, p = 0.021) and provided significant net reclassification (NRI 0.506, p < 0.001) and integrated discrimination improvement (IDI 0.212, p < 0.001). CONCLUSIONS: In STEMI patients with preserved LVEF, early fibroblast activation measured by ⁶⁸Ga FAPI 46 PET/CT is associated with subsequent left ventricular remodeling. FAV may provide incremental prognostic value beyond traditional risk factors. These findings are exploratory, and warrant validation in larger, multicenter cohorts and comparisons with other relevant imaging methods.
引用
- Liang L, Yu L, Ruan D, et al. Early post-infarct fibroblast activation protein-targeted PET/CT with 68Ga-FAPI-46 identifies STEMI patients with preserved LVEF at higher risk for adverse remodeling and cardiovascular events. Eur J Nucl Med Mol Imaging. 2026. PMID: 42477144. doi:10.1007/s00259-026-08081-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。